MRKR

+ Watchlist + Portfolio

Marker Therapeutics, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.05
52-Week Range: $0.84 – $2.46
Market Cap: $17.51M
P/E (TTM): —
EPS (TTM): -0.42
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.44
PEG Ratio: —
Return on Equity: -76.87%
Return on Assets: -40.47%
Gross Margin: -148.28%
Operating Margin: -267.95%
Profit Margin: -245.51%
Current Ratio: 6.03
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-6.23M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $6.18M

MRKR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$3.31M	$0.00	$0.00
Research & Development	$11.97M	$10.42M	$13.47M	$11.80M
Selling, General & Admin	$11.34M	$7.48M	$4.24M	$4.18M
Operating Expenses	$19.79M	$14.58M	$11.12M	$12.44M
Operating Income	-$19.79M	-$11.27M	-$11.12M	-$12.44M
EBITDA	-$19.79M	-$11.27M	-$11.12M	-$12.44M
Pretax Income	-$19.78M	-$10.73M	-$10.68M	-$12.18M
Income Tax	$0.00	$3.67K	$49.95K	-$15.16K
Net Income	-$29.93M	-$8.24M	-$10.73M	-$12.16M
Diluted EPS	-3.58	-0.94	-1.19	-0.79
Diluted Shares	8.35M	8.81M	8.98M	15.31M

MRKR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$11.78M	$15.11M	$19.19M	$16.07M
Receivables	$2.40M	$1.03M	$2.35M	$1.37M
Current Assets	$16.62M	$17.13M	$22.02M	$19.07M
Total Assets	$34.42M	$17.13M	$22.02M	$19.07M
Current Liabilities	$7.78M	$3.07M	$3.46M	$2.27M
Total Debt	$7.62M	—	—	—
Total Liabilities	$14.82M	$3.07M	$3.46M	$2.27M
Retained Earnings	-$428.05M	-$436.29M	-$447.02M	-$459.18M
Shareholders' Equity	$19.60M	$14.05M	$18.56M	$16.80M
Working Capital	$8.84M	$14.05M	$18.56M	$16.80M

MRKR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$26.97M	-$16.44M	-$10.91M	-$12.01M
Capital Expenditure	-$4.95M	—	—	—
Free Cash Flow	-$26.97M	-$16.44M	-$10.91M	-$12.01M
Depreciation & Amortisation	$3.68M	—	—	—
Stock-Based Compensation	$3.30M	$858.27K	$245.86K	$537.54K
Investing Cash Flow	-$4.95M	$18.66M	$0.00	—
Financing Cash Flow	$202.13K	$1.11M	$14.99M	$9.86M
Net Change in Cash	-$31.72M	$3.33M	$4.08M	-$2.15M

MRKR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.14M	$4.18M	$2.35M	$2.14M	$2.84M	$1.48M
Selling, General & Admin	$1.37M	$945.16K	$1.02M	$846.61K	$1.23M	$1.14M
Operating Expenses	$4.16M	$4.26M	$2.14M	$1.88M	$3.32M	$1.94M
Operating Income	-$4.16M	-$4.26M	-$2.14M	-$1.88M	-$3.32M	-$1.94M
EBITDA	-$4.16M	-$4.26M	-$2.14M	-$1.88M	-$3.32M	-$1.94M
Pretax Income	-$4.45M	-$4.02M	-$2.00M	-$1.72M	-$3.18M	-$1.83M
Net Income	-$4.45M	-$4.02M	-$2.00M	-$1.70M	-$3.18M	-$1.83M
Diluted EPS	-0.40	-0.29	-0.12	—	-0.16	-0.09
Diluted Shares	11.11M	13.96M	16.76M	—	19.31M	19.31M

MRKR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$13.69M	$10.46M	$17.59M	$16.07M	$14.92M	$11.33M
Receivables	$2.46M	$1.67M	$1.67M	$1.37M	$1.38M	$1.62M
Current Assets	$16.99M	$14.77M	$21.73M	$19.07M	$17.43M	$14.59M
Total Assets	$16.99M	$14.77M	$21.73M	$19.07M	$17.43M	$14.59M
Current Liabilities	$2.50M	$4.28M	$3.35M	$2.27M	$3.64M	$2.42M
Total Liabilities	$2.50M	$4.28M	$3.35M	$2.27M	$3.64M	$2.42M
Retained Earnings	-$451.46M	-$455.48M	-$457.48M	-$459.18M	-$462.36M	-$464.19M
Shareholders' Equity	$14.49M	$10.49M	$18.39M	$16.80M	$13.80M	$12.17M
Working Capital	$14.49M	$10.49M	$18.39M	$16.80M	$13.80M	$12.17M

MRKR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$5.50M	-$1.88M	-$2.74M	-$1.90M	-$1.40M	-$3.72M
Free Cash Flow	-$5.50M	-$1.88M	-$2.74M	-$1.90M	-$1.40M	-$3.72M
Stock-Based Compensation	$379.14K	$13.99K	$33.28K	$111.13K	$178.42K	$195.74K
Financing Cash Flow	$505.00	$100.00	$9.86M	$0.00	$0.00	$0.00
Net Change in Cash	-$5.50M	-$1.88M	$7.13M	-$1.90M	-$1.40M	-$3.72M

Market Snapshot

About

Clinical-stage immuno-oncology company developing T cell-based therapies to treat hematologic malignancies and solid tumors. Lead programs utilize multi-targeted autologous tumor infiltrating lymphocytes (TIL) designed to recognize and kill cancer cells with multiple antigens. Focus on accessible off-the-shelf solutions.